NASDAQ:TRIL - Trillium Therapeutics Stock Price, Forecast & News

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Trillium Therapeutics Inc (NASDAQ:TRIL) issued its earnings results on Friday, May, 11th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.13. View Trillium Therapeutics' Earnings History.

Trillium Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Trillium Therapeutics.

2 brokers have issued 12-month target prices for Trillium Therapeutics' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Trillium Therapeutics' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for Trillium Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics.

News stories about TRIL stock have trended negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Trillium Therapeutics.

Trillium Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,940,000 shares, an increase of 399.6% from the January 15th total of 788,700 shares. Based on an average daily trading volume, of 3,600,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 6.4% of the company's stock are sold short. View Trillium Therapeutics' Current Options Chain.

Some companies that are related to Trillium Therapeutics include Mirum Pharmaceuticals (MIRM), Avid Bioservices (CDMO), Avedro (AVDR), Recro Pharma (REPH), Urovant Sciences (UROV), DURECT (DRRX), Progenics Pharmaceuticals (PGNX), Calithera Biosciences (CALA), Mallinckrodt (MNK), Galera Therapeutics (GRTX), Verrica Pharmaceuticals (VRCA), Rigel Pharmaceuticals (RIGL), Lannett (LCI), Kindred Biosciences (KIN) and Corbus Pharmaceuticals (CRBP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), Agile Therapeutics (AGRX), Karyopharm Therapeutics (KPTI), TG Therapeutics (TGTX) and AcelRx Pharmaceuticals (ACRX).

Trillium Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.10%).

TRIL stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRIL stock can currently be purchased for approximately $4.16.

Trillium Therapeutics has a market capitalization of $116.64 million. The biotechnology company earns $-25,290,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. View Additional Information About Trillium Therapeutics.

The official website for Trillium Therapeutics is http://www.trilliumtherapeutics.com/.

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]